News | Breast Imaging | August 25, 2015

Software Finds and Separates Benign From Malignant DCIS and Breast Cancer

mammography, women's health

A California software company, www.YourScan.org, has put out a call to women who have had to face the difficult diagnosis of breast cancer: Donate your mammogram images to a crowdsourcing campaign and help confirm that a new visual recognition software presents a breakthrough in early detection and distinguishing benign from malignant precursors (DCIS) and lesions through the use of "Lesion Tissue Profiling (LTP)."

In a pilot test conducted over the last three years, the company has shown that its Lesion Tissue Profiling technology is capable of accurately detecting the shapes of malignant DCIS and tumors (lesions) otherwise not visible to the human eye. The study further indicated that these lesions have a limited number of basic shapes that can be rendered as distinct tissue profiles common to all malignancy. The implication is that these profiles may be used as a tool in routine screening of all mammography. This could present an important breakthrough — the first automated digital search of the more than 30 million mammograms done in the US each year, a search that would offer valuable diagnostic insight.

The company, YourScan.org, has built a proprietary database specifically designed to store mammographic images in a format allowing for rapid and precise comparison of billions of tissue profiles. The data is highlighted using a visual-based color illustrator and the technology catalogues each shape – assembling a "tissue profile" that can be matched with other tissue profiles.  Searching "healthy" mammograms using those tissue profiles has revealed that the technology can detect "precursor" (DCIS) tissue profiles in digital mammograms, both two-dimensional and newer 3-D images produced by tomosynthesis technology. The Company is asking women diagnosed with breast cancer to provide their entire series of mammograms to compare earlier mammograms to the later one that resulted in a definitive diagnosis; identifying and cataloging precursor and lesion tissue profiles found in their mammograms. These newly identified tissue profiles will be added to the tissue profile library, and used to search other mammograms for breast cancer precursors and lesions.

For more information: www.YourScan.org.

Related Content

Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...
Hologic Acquires Digital Specimen Radiography Company Faxitron Bioptics

VisionCT 3-D breast specimen-designated computed tomography (CT) system. Image courtesy of Faxitron Bioptics.

News | Breast Imaging | July 31, 2018
Hologic Inc. announced it has completed the acquisition of Faxitron Bioptics, a privately-held leader in digital...
Konica Minolta Hosting Lunch and Learn at 23rd Annual Mammography Meeting in Santa Fe
News | Breast Imaging | July 31, 2018
Konica Minolta Healthcare Americas Inc. will sponsor a lunch and learn featuring its Exa Mammo platform during the 23rd...
FDA Approves New Tomosynthesis Quality Control Tests for ACR Digital Mammography QC Manual
News | Mammography | July 30, 2018
The U.S. Food and Drug Administration (FDA) recently approved the American College of Radiology’s (ACR’s) amendment to...
The Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal. The FDA granted approval of the Sentimag System to Endomagnetics Inc.

The  Endomagnetics' Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal.

Technology | Women's Health | July 24, 2018
July 24, 2018 — The U.S.
Overlay Init